GleamWall
中文EN

CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1187953 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.0%
TTM net income YoY-25.4%
TTM EPS YoY29.9%
Revenue 3-yr CAGR-50.4%
Net income 3-yr CAGR—

Margins

Gross margin66.9%
Operating margin-256,435.0%
Net margin-249,160.1%
FCF margin—
EBITDA margin—

Returns

ROE-119.2%
ROA-113.8%
ROIC (approx.)-3,736.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets4.0%
Debt / equity0.00x
Current ratio23.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-16.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$3,000$0$0$3,000$3,000
Cost of revenue$0$0$0$994$0$0$1,200$1,200
Gross profit$0$0$0$2,006$0$0$1,800$1,800
R&D expense$1.60M$459,200$541,658$550,077$465,154$501,261$743,304$471,840
SG&A expense$1.11M$1.08M$888,640$1.37M$776,821$731,517$888,397$1.39M
Operating income-$2.73M-$1.56M-$1.46M-$1.95M-$1.27M-$1.26M-$1.66M-$1.89M
Pretax income-$2.66M-$1.51M-$1.40M-$1.89M-$1.24M-$1.23M-$1.64M-$1.85M
Income tax$0$0$0$0$0$0$0$0
Net income-$2.67M-$1.51M-$1.41M-$1.89M-$1.24M-$1.23M-$1.64M-$1.85M
EBITDA——————-$1.61M-$1.88M
EPS (diluted)-0.40-0.41-0.38—-0.48-0.48-0.83—
Weighted avg. shares (diluted)6.66M3.70M3.70M—2.58M2.58M1.98M—
Balance sheet
Cash & equivalents$6.85M$8.71M$5.72M$7.21M$5.38M$6.55M$7.70M$5.94M
Inventory—$125,000$125,000$0$994$994$994$2,194
Current assets$6.94M$9.02M$6.06M$7.40M$5.41M$6.63M$7.84M$6.14M
Intangibles$338,806$355,459$378,377$407,230$438,181$469,240$499,982$530,559
Total assets$7.28M$9.38M$6.44M$7.81M$5.85M$7.11M$8.35M$6.67M
Current liabilities$293,226$698,595$307,649$284,880$261,353$277,644$286,387$327,644
Total liabilities$293,226$698,595$307,649$284,880$261,353$277,644$286,387$327,644
Shareholders' equity$6.95M$8.65M$6.11M$7.51M$5.59M$6.83M$8.06M$6.34M
Shares outstanding7.60M6.49M3.70M3.70M2.58M2.58M2.58M1.75M
Cash flow statement
Operating cash flow-$1.66M-$1.47M-$1.32M-$1.94M-$1.17M-$1.16M-$1.59M-$1.95M
Investing cash flow$203,140$0-$175,000-$50,500$0$0$0$0
Financing cash flow-$407,164$4.46M$13,360$3.82M$0$0$3.35M$1.63M
Depreciation & amortization——————$46,000$10,000
Stock-based compensation$970,000$0$0$0$0$0$3,485$9,162
Share buybacks$0$0$0$0$0$0$10,000$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.